Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABACUS-2 neoadjuvant atezolizumab in urothelial cancer
2024-510750-28-00Phase 2Completed
- Sponsor
- Queen Mary University of London
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label trial of atezolizumab in transitional cell carcinoma (TCC), upper tract urothelial carcinoma (UTUC) and bladder cancer (2 cohorts), sponsored by Queen Mary University of London. Primary endpoints: Pathological complete response rate in bladder cohort and Pathological complete response rate in upper urinary tract cohort. Started Jun 2021; status: completed.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)upper tract urothelial carcinoma (UTUC)bladder cancer
Beyond the preview
Go deeper on 2024-510750-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510750-28-00.